LENSAR (NASDAQ:LNSR) vs. Baxter International (NYSE:BAX) Financial Review

Baxter International (NYSE:BAX – Get Free Report) and LENSAR (NASDAQ:LNSR – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Baxter International and LENSAR, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baxter International 3 10 1 0 1.86
LENSAR 1 0 2 0 2.33

Baxter International currently has a consensus target price of $23.27, indicating a potential downside of 8.83%. LENSAR has a consensus target price of $11.00, indicating a potential upside of 107.94%. Given LENSAR’s stronger consensus rating and higher possible upside, analysts clearly believe LENSAR is more favorable than Baxter International.

Insider and Institutional Ownership

90.2% of Baxter International shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 0.2% of Baxter International shares are owned by insiders. Comparatively, 65.8% of LENSAR shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Baxter International has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, LENSAR has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.

Earnings & Valuation

This table compares Baxter International and LENSAR”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Baxter International $11.61 billion 1.14 -$957.00 million ($1.41) -18.10
LENSAR $60.08 million 1.08 -$34.28 million ($0.40) -13.22

LENSAR has lower revenue, but higher earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than LENSAR, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Baxter International and LENSAR’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Baxter International -6.23% 16.23% 5.08%
LENSAR 56.07% 1,254.25% 49.13%

Summary

LENSAR beats Baxter International on 11 of the 14 factors compared between the two stocks.

About Baxter International

(Get Free Report)

Baxter International is a global healthcare company that develops and supplies products used in hospitals, clinics and other care settings. Its offerings include intravenous solutions and administration sets, infusion pumps, medication-delivery systems, and products for surgical and hospital care. The company also provides patient-monitoring and connected-care technologies, including products associated with Hillrom, which Baxter acquired in 2021. Its products and services support healthcare professionals and patients in countries around the world.

About LENSAR

(Get Free Report)

LENSAR, Inc. develops and markets laser-based technology for ophthalmic surgery, with a focus on procedures used to treat cataracts. Its systems are designed to assist surgeons with key steps in cataract surgery, including the creation of incisions and the fragmentation of the eye’s natural lens. The company’s products include the ALLY Adaptive Cataract Treatment System and the LENSAR Laser System, which use imaging and software to support surgical planning and treatment. LENSAR also offers related software, accessories and services for ophthalmic practices and surgical facilities.

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.